LJI-308

N/A

Report date: 2023/01/01 20:06:12
NME

Base Information

Drug NameLJI-308
Drug Alias NameLJI-308
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRibosomal protein S6 kinase inhibitors
TargetsRibosomal protein S6 kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A